


Report of the Directors and Financial Statements
For the period 17th November 2014 to 30th November 2015
For
Oxford Biomaterials Holdings Limited

Registered Number
09315175



Oxford Biomaterials Holdings limited

Report of the Directors and Unaudited Financial Statements for the Period 17th

November 2014 to 30th November 2015

Contents

	Page
Company Information	2
Directors' Report	3
Balance Sheet	4
Note to the Financial Statements	5

Oxford Biomaterials Holdings limited

Report of the Directors and Unaudited Financial Statements for the Period 17th

November 2014 to 30th November 2015

Company Information

Directors

FWL Vollrath
D P Knight
D C Bott

Registered Number

09315175

Address and Registered Office

Magdalen Centre Oxford Science Park
Oxford
OX4 4GA

Oxford Biomaterials Holdings limited

Directors' Report

The directors present their report and the financial statements for the period 17th November 2014 to 30th November 2015.

Incorporation

The Company was incorporated on 17th November 2014

Directors

The following directors were appointed on 17th November 2014 and have remained in office to 30th November 2015:

FWL Vollrath
D P Knight
D C Bott

Directors' Responsibilities

The directors are responsible for preparing the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial period. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing those financial statements, the directors are required to:

- select suitable accounting policies and apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- prepare the financial statements on a going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The report of the directors' has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

This report was approved by the board on 15th August 2016

Dr David Bott

Director



Oxford Biomaterials Holdings limited
Balance Sheet
As at 30th November 2015

	Notes	2015 £
Fixed Assets		
Investment	2	904,595
		<hr/>
Net Assets		904,595
		<hr/>
Capital and reserves		
Called up share capital	3	904,595
		<hr/>
Shareholders' Funds		904,595
		<hr/>

The directors are satisfied that the company is entitled to exemption from audit under Section 477 of the Companies Act 2006 and that no member or members have requested an audit pursuant to section 476 of the Act.

The financial statements have been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006 and with the Financial Reporting Standard for Smaller Entities (effective January 2015)

The financial statements were approved by the Board of Directors on 15/08/2016 and were signed on its behalf by:

David Bott

Director



Oxford Biomaterials Holdings limited
Notes to the Financial Statements
for the Period 17th November 2014 to 30th November 2015

1 Accounting Policies

Accounting Convention

The financial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective January 2015).

2 Investment

At the balance sheet date the company holds 100% of the issued share capital of Oxford Biomaterials Ltd

The net investment in Oxford Biomaterials Ltd is made up as below

Nominal value of 180,919 Ordinary shares of £ 0.01 each in Oxford Biomaterials Ltd	£ 1,809
--	---------

Goodwill on the purchase of Oxford Biomaterials Ltd shares	5,425,761
--	-----------

Unsecured loan from Oxford Biomaterials Ltd to Oxford Biomaterials Holding Ltd arising on the purchase of the Orthox Ltd shareholding by Oxford Biomaterials Holdings limited from Oxford Biomaterials	(4,522,975)
--	-------------

At 30 th November 2015	£ 904,595
-----------------------------------	-----------

3 Share Capital

2015

£

Allotted, called up and fully paid

Ordinary shares of £0.01 each	904,595
-------------------------------	---------

542,756,999 ordinary shares of £ 0.01 each were allotted and fully paid at par on 9th February 2015

452,297,500 ordinary shares of £ 0.01 each were cancelled and extinguished on 11th March 2015